SEC Form 3 · accession 0001104659-16-164586
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Peter Wolf III
Officer — General Counsel and Corp. Sec.
Period of report
Dec 30, 2016
Accepted (ET)
Dec 30, 2016 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | holding | — | — | — | 270 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3,F2 | — | holding | — | — | — | — | Sep 29, 2025 | Common Shares | 5,500 | — | D |
| Stock OptionF5,F4 | — | holding | — | — | — | — | Feb 4, 2026 | Common Shares | 5,590 | — | D |
Explanation of responses
- F1Represented by 2,700 American Depositary Shares.
- F2This option was granted on September 30, 2015. Vesting began on September 30, 2015 and ends on September 30, 2019. Twenty-five percent (25%) of the option vested on September 30, 2016, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
- F3The exercise price is 84.80 Euro.
- F4This option was granted on February 5, 2016. Vesting began on February 29, 2016 and ends on February 29, 2020. Twenty-five percent (25%) of the option will vest on February 28, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
- F5The exercise price is 74.45 Euro.